Minerva Neurosciences, Inc. is a biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS), diseases. The Company�s product candidates are MIN-101, a compound it is developing for the treatment of patients with schizophrenia, and MIN-117, a compound it is developing for the treatment of patients suffering from depressive disorder (MDD). In addition, the Company�s portfolio includes MIN-202, a compound it is co-developing for the treatment of patients suffering from primary and secondary insomnia, and MIN-301, a compound it is developing for the treatment of patients suffering from Parkinson's disease. Its product candidates include MIN-101, MIN-117, MIN-202 and MIN-301.